Press Releases

Date Title
September 2, 2020 Progenity to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that Harry Stylli, Ph.D., CEO, chairman of the board, and co-founder of
August 21, 2020 Progenity Commends New Recommendations from ACOG and SMFM Supporting Non-Invasive Prenatal Testing (NIPT) for All Pregnancies
SAN DIEGO, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products including NIPT, commends the recent guideline update from the American College of
August 13, 2020 Progenity Provides Corporate Updates and Reports Second Quarter 2020 Financial Results
Completed initial public offering raising gross proceeds of $100M Reported 75 thousand tests in the second quarter, showing resiliency of business during COVID‑19 pandemic Signed first precision medicine program pharma deal Management will host conference call and webcast today at 4:30 p.m.
August 6, 2020 Progenity to Report Second Quarter 2020 Financial Results
SAN DIEGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it will report second quarter 2020 financial results on Thursday,
July 23, 2020 Progenity Reaches Resolution with Government Related to Past Business, Promotional, and Billing Practices
The Company has established and continues to make significant investments in industry-leading compliance protocols and reporting standards SAN DIEGO, July 23, 2020 (GLOBE NEWSWIRE) -- Progenity , Inc. (Nasdaq: PROG), a biotechnology company focused on providing complex molecular and specialized
June 19, 2020 Progenity Announces Pricing of Initial Public Offering
SAN DIEGO, June 19, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc . (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced the pricing of its initial public offering of 6,666,667 shares of common
May 27, 2020 Progenity Shares Posters Identifying Key Factors for Clinical Decision Making
The four posters were released for the 2020 American College of Medical Genetics and Genomics’ (ACMG) Annual Clinical Genetics Meeting. SAN DIEGO, May 27, 2020— Progenity, a biotechnology company with an established track record of success in developing and commercializing molecular testing
May 26, 2020 Progenity Adds Operational Expertise to Leadership Team with Appointment of Damon Silvestry as COO
Mr. Silvestry will be focused on delivering operational excellence, achieving ambitious growth targets, and driving the company’s service culture. SAN DIEGO, May 26, 2020— Progenity, a biotechnology company with an established track record of success in developing and commercializing molecular
March 30, 2020 Progenity Appoints Troy Seelye as CIO
Mr. Seelye will help to strengthen our technology and data strategy, leading the development of key products and services designed to transform the customer experience. SAN DIEGO, March 30, 2020— Progenity, a biotechnology company with an established track record of success in developing and
March 26, 2020 Progenity Offers Enhanced Services During the COVID-19 Pandemic
Our lab is fully operational and we are offering assisted patient education and collection services to support healthcare providers and patients. Recent public health measures related to the novel coronavirus are greatly impacting healthcare practices.
Displaying 31 - 40 of 60